[go: up one dir, main page]

MX2021002974A - Mejora del sue?o o del rendimiento despues de dormir. - Google Patents

Mejora del sue?o o del rendimiento despues de dormir.

Info

Publication number
MX2021002974A
MX2021002974A MX2021002974A MX2021002974A MX2021002974A MX 2021002974 A MX2021002974 A MX 2021002974A MX 2021002974 A MX2021002974 A MX 2021002974A MX 2021002974 A MX2021002974 A MX 2021002974A MX 2021002974 A MX2021002974 A MX 2021002974A
Authority
MX
Mexico
Prior art keywords
sleep
post
improving
performance
improving sleep
Prior art date
Application number
MX2021002974A
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Changfu Xiao
Christos Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2021002974A publication Critical patent/MX2021002974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere en general a la mejora del sueño, del rendimiento después de dormir, o de ambos, y, más particularmente, a dicha mejora sin inducir efectos después del dormir que podrían deteriorar la capacidad de una persona para operar maquinaria o un vehículo a motor.
MX2021002974A 2018-09-12 2019-09-12 Mejora del sue?o o del rendimiento despues de dormir. MX2021002974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730467P 2018-09-12 2018-09-12
PCT/US2019/050785 WO2020056117A1 (en) 2018-09-12 2019-09-12 Improving sleep or post-sleep performance

Publications (1)

Publication Number Publication Date
MX2021002974A true MX2021002974A (es) 2021-05-12

Family

ID=68069875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002974A MX2021002974A (es) 2018-09-12 2019-09-12 Mejora del sue?o o del rendimiento despues de dormir.

Country Status (12)

Country Link
US (2) US20210353586A1 (es)
EP (1) EP3849531A1 (es)
JP (2) JP2022500420A (es)
KR (1) KR20210060489A (es)
CN (1) CN113365618A (es)
AU (2) AU2019337627A1 (es)
BR (1) BR112021004214A2 (es)
CA (1) CA3112202A1 (es)
MX (1) MX2021002974A (es)
PH (1) PH12021550365A1 (es)
SG (1) SG11202101828PA (es)
WO (1) WO2020056117A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274183C (en) * 1996-12-10 2006-10-24 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
RU2650647C2 (ru) * 2012-01-26 2018-04-16 Ванда Фармасьютиклз Инк. Лечение нарушений циркадного ритма
AU2013262631B2 (en) * 2012-05-18 2016-02-04 Vanda Pharmaceuticals Inc. Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
KR20240015729A (ko) * 2014-09-02 2024-02-05 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
JP2016204281A (ja) * 2015-04-17 2016-12-08 国立研究開発法人産業技術総合研究所 概日リズム改善剤
WO2017098367A1 (en) * 2015-12-10 2017-06-15 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain

Also Published As

Publication number Publication date
WO2020056117A1 (en) 2020-03-19
US20240226056A1 (en) 2024-07-11
EP3849531A1 (en) 2021-07-21
KR20210060489A (ko) 2021-05-26
SG11202101828PA (en) 2021-04-29
AU2025204400A1 (en) 2025-07-03
PH12021550365A1 (en) 2021-10-25
BR112021004214A2 (pt) 2021-05-25
AU2019337627A1 (en) 2021-04-01
US20210353586A1 (en) 2021-11-18
JP2022500420A (ja) 2022-01-04
JP2024149609A (ja) 2024-10-18
CA3112202A1 (en) 2020-03-19
CN113365618A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
JP2019046670A5 (es)
JP2018189175A5 (es)
JP2020104561A5 (es)
JP2019158088A5 (es)
WO2018178334A3 (fr) Purification des phycobiliproteines
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2022006154A (es) Combinaciones y sus usos.
MY185952A (en) Suspension device
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
WO2018135843A3 (ko) 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물
USD847266S1 (en) Adinkra card game
NZ746539A (en) Combination,therapeutic uses and prophylactic uses
CA195631S (en) Portion of fan
SG10201803158VA (en) Electromechanical transducer
PH12018550149B1 (en) Beta-caseins and cognitive function
PH12021550365A1 (en) Improving sleep or post-sleep performance
JP2019094024A5 (es)
GB202015822D0 (en) 66.123.142648/01
WO2016019306A3 (en) Abrasive article including z-shaped abrasive segments
JP2021101085A5 (es)
AU2018250922A1 (en) Shock-absorbing seat having wall-mounted damping members
JP2020048126A5 (es)
JP2020034264A5 (es)
SG10201809621XA (en) Plate